Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 181 - 190 of 333

<< Previous | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | Next >>

Last updated: 20th February 2008

Patent No.: WO 040069
Bioactive surgical suture.
Applicant: Shibuya TY (2002)
The application concerns bioactive surgical suture which is surgical suture coated with one or more biologically active compounds. The bioactive suture is used for a variety of purposes, including treatment of disease. Immunomodulating suture of the present invention is used in the treatment of a patient with head and neck cancer. First, a suture coated with human defensin is placed into the palpable regional lymph node. This attracts immature CD34+ antigen presenting cells that are believed to be immunosuppressive. After several days of attracting these cells to the area within the lymph node near the suture, the defensin coated suture is removed and replaced with an CD31 CD28 coated suture. This suture stimulates the immature cells to become more mature antigen presenting cells. The CD3 CD28 suture is removed after several days and replaced with a suture coated with antigens specific to the type of cancer found in the patient. This suture produces an immune specific response. A second suture is then added to help boost the specific immune response. The second suture is coated with CD31 CD28 antibody. This combination of immuno-modulating sutures stimulates the lymph node lymphocytes to kill the cancer.

Patent No.: WO 022686
Fusion proteins comprising defensin and human tumor antigen or viral antigen for treating cancer and viral infection.
Applicant: Kwak LW, Biragyn A (2002)
The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection. The defensin is human beta-defensin 1, human beta-defensin 2, human neutrophil peptide 1 (HNP-1), HNP-2, HNP-3, murine beta-defensin 2, murine beta-defensin 3, etc.; the tumor antigen is B cell lymphoma antigen, MUC-1, etc.; and the viral antigen is HIV-1 gp120, gp160, gp41, etc. The fusion proteins may also comprise immunostimulatory cytokine or chemokine.

Patent No.: WO 012293
Polynucleotides and polypeptides for hypersensitive response elicitor from Xanthomonas campestris, and their uses.
Applicant: Wei Z-M, Swanson SS (2002)
The present invention is directed to an isolated DNA mol. encoding a Xanthomonas hypersensitive response elicitor protein or polypeptide. The DNA mol. and its encoded hypersensitive response elicitor protein or polypeptide have the following uses: imparting disease resistance to plants, enhancing plant growth, controlling insects on plants, imparting stress resistance, imparting post-harvest disease resistance, maximizing the benefit of or overcoming a yield penalty assocd. with a transgenic trait, inhibiting desiccation of cuttings from ornamental plants, promoting early flowering of an ornamental plant, and harvesting cuttings from ornamental plants. These can be achieved by applying the hypersensitive response elicitor in a non-infectious form to plants or plant seeds (or cuttings or fruits or vegetables harvested from such plants) or by expression of the hypersensitive response elicitor in transgenic plants. Expression vectors, host cells transgenic plants, transgenic plant cuttings, and transgenic plant seeds are also disclosed. Genomic DNA encoding the hypersensitive response elicitor protein from Xanthomonas campestris pelargonii was cloned and the recombinantly expressed protein was active in tobacco. Results of Southern blot hybridizations with a gene hreX probe suggest that the gene is present in many Xanthomonas species.

Patent No.: WO 009738
Organ transplant media containing antimicrobial polypeptides.
Applicant: Murphy CJ, Reid T, McAnulty JF (2002)
The present invention relates to media containing purified antimicrobial polypeptides, such as bovine dodecapeptide (BNP-1), and/or cell surface receptor binding proteins. The media may also contain buffers, macromol. oncotic agents, energy sources, impermeant anions, ATP substances. The media finds use in the storage and preservation of internal organs prior to transplant.

Patent No.: WO 006821
Antimicrobial agent.
Applicant: Bjorck L, Frick I-M, Schmidtchen A (2002)
A method of identifying an agent that enhances the anti-microbial activity of cationic anti-microbial peptides by blocking the inhibitory effects of the proteinase/glycosaminoglycan pathway, which method comprises: (i) providing, as a first component, a cationic anti-microbial peptide; (ii) providing, as a second component, bacteria; (iii) providing, as a third component, part of all of the components of a proteinase/glycosaminoglycan pathway such that the third component reduces the antimicrobial effect of the first component, for example, a glycosaminoglycan or bacteria or bacteria and a proteoglycan or a bacterial proteinase or a bacterial proteinase and a proteoglycan; (iv) contacting the first, second and third components with a test agent under conditions that would permit the killing of the bacteria by the antimicrobial agent in the absence of the third component, and that would permit the inhibition of the anti-microbial activity of the first component by the third component in the absence of the test agent; (v) monitoring the survival of the bacterial culture thereby detg. whether the test agent is capable of enhancing anti-microbial activity wherein a test agent capable of enhancing anti-microbial activity promotes killing of the bacterial culture. Agents identified by such a method are useful in the therapy of acute and chronic infections, particularly in the treatment of ulcers and in the promotion of wound healing.

Patent No.: WO 004487
Method for producing and using novel human beta-defensins as biologically active proteins for treating infections and other illnesses.
Applicant: Forssmann WG, Conejo-Garcia JR, Adermann K (2002)
The invention relates to novel peptides taken from human blood, hBD-5 (human beta-defensin 5), hBD-6, hBD-7, hBD-8, hBD-10, hBD-11, hBD-12, hBD-13, hBD-14, hBD-15, hBD-16, hBD-17, hBD-18, hBD-19, hBD-20, hBD-22, hBD-23, hBD-24, hBD-25, hBD-26, hBD-27, hBD-28, hBD-29, hBD-30, hBD-31 and hBD-32 and the derivatives thereof, the structure of the same having been elucidated so that they can be used therapeutically, diagnostically and com. as drugs. Said peptides can be produced by means of biotechnology, recombinant methods and chemical synthesis, and can be proteolytically derived from corresponding precursor proteins.

Patent No.: WO 000706
Termite defensin termicin and cDNA and their use in protection of plants from phytopathogenic fungi.
Applicant: Lamberty M, Bulet P, Latorse M, Hoffmann J (2002)
The invention concerns an antimicrobial peptide of the family of defensins, in particular antifungal, called termicin, DNA encoding said peptide, vectors contg. them for transforming a host organism and the method for transforming said organism. The invention also concerns transformed organisms, in particular yeast, or plant cells and plants, the termicin produced by the transformed plants providing them with resistance to fungus-mediated diseases. Thus, the cDNA for Pseudacanthotermes spiniger termicin was expressed in Saccharomyces cerevisiae. The yeast MFalpha1 promoter, prepro- sequence, and terminator were used to control expression and protein secretion. The recombinant termicin exhibited antifungal activity against Cercospora fifensis, Botrytis cinerea, Septoria nodorum, S. tritici, Rhizoctonia solani, Fusarium graminearum, and F. nivale.

Patent No.: US 6476189
Antibacterial peptides and antibacterial agents containing such peptides as an effective ingredient.
Applicant: Yamakawa M, Ishibashi J, Sakanaka H (2002)
Antibacterial peptides X-Ala-Ile-Arg-Lys-Arg-NH2 (X is Ala-Xaa1-Xaa2-Leu, where Xaa1 and Xaa2 are nonacidic amino acid residues) derived from Oryctes rhinoceros and their formulations are described. The peptides are of high safety, improved activity, wide antibacterial spectrum, and low mol. wt. Due to the low mol. wt., the effects of these peptides on immune system in vivo are decreased. The antibacterial peptides exhibited high antibacterial activity with min. inhibitory concn. (MIC) of 2-5 microg/mL against Staphylococcus aureus, 25-40 microg/mL against methicillin-resistant Staphylococcus aureus (MRSA), 4-10 microg/mL against Escherichia coli and 4->15 microg/mL against Pseudomonas aeruginosa. Toxicity of the peptides was tested in mice showing LD50 of > 150 mg/kg. A granule formulation was prepd. by mixing 500 mg the peptide with 50 mg of cryst. cellulose and 450 mg lactose, followed by blending together with 1 mL of an EtOH-H2O mixt. and granulation.

Patent No.: US 110553
Use of antibiotic peptides produced by human corneal epithelial cells to manage infection.
Applicant: Fleiszig SMJ, McNamara NA (2002)
The antibiotic polypeptide beta-defensin-2 (hBD-2) is expressed in the eye, and is useful for treating ocular wounds. HBD-2 may be administered to the eye, or its endogenous expression may be upregulated by administering an hBD-2 stimulating compd.

Patent No.: WO 9421672
Beta-defensins: novel antimicrobial peptides from bovine neutrophils.
Applicant: Selsted ME, Cullor JS (2001)
A new family of cysteine-rich antimicrobial peptides isolated from bovine neutrophils, beta-defensins, are purified and characterized for use in human and veterinary medicine, and as agents in agricultural, food science, and industrial applications. Thirteen structurally homologous peptides were purified to homogeneity from a granule-rich cytoplasmic fraction of purified blood neutrophils. The proteins were purified from PMN granules by solubilization with 10% acetic acid and fractionation of redissolved lyophilized ext. on BioGel-P60 and reveres-phase HPLC on a Vydac C-18 column. Active fractions were identified by an antimicrobial radial diffusion assay using Escherichia coli and Staphylococcus aureus with active concns. lying in the range 10-300 microg/mL. Some of the peptides were also very active against fungi (Candida albicans).